• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    X-RAY MEDIA containing a contrast agent and water, characterized by that. that, in order to increase water solubility and to reduce viscosity, as a contrast agent, it contains bis-
    公开号:SU1087052A3
    申请号:SU802953751
    申请日:1980-08-08
    公开日:1984-04-15
    发明作者:Фельдер Эрнст；Питре Давид
    申请人:Бракко Индустрия Кимика С.П.А. (Фирма)；
    IPC主号:
    专利说明:

    This invention relates to medicine and relates to a radiopaque medium that can be used in angiography, urography and tomography X-ray contrast medium containing contrast agent and water is known. However, the well-known X-ray contour has high viscosity and insufficient water-soluble properties. The aim of the invention is to increase the water solubility and decrease viscosity. Postavleina, the goal is achieved by the fact that, in a radiopaque agent containing a contrasting substance n water, as a contrac, the substance contains bis- (2.5 where (HOX alkyl 1,3-dioxyisopropyl 2,3-dioxypropyl or 1, 3-dioxy-2- hydroxymethyl isopropyl hydrogen, or methyl, is a contrast agent that is characterized by high water solubility and (Ho)., jff / 7 "i / fl-NH-do (LO) o K / l-nH- (1 g-3 s an alkylating agent of the general formula Kr (lt) where R and R | are a halogen atom, 1, Br, C1 or sulphate or a sulphonate residue (-OSOji-OR, -OS02-alcr or -050 aryl), or nnosposobnoe functional derivative 5S rA Noe 5- (N-alkyl-h (goksiatsilamino) -2,4,6-triyodizoftalevoy. acid of the general formula
    (I)
    dO- (JH (4) H) -R dioxypropylamide) 5- (P-methyloxyacetylamino) -2,4,6-triiodoisophthalic acid or bis- (1,3-dioxyisopropylamide) 5- (K-methyl-o6-oxypropionylamino) -2,4,6-triiodoisophthalic acid in the following ratio of ingredients, wt.%: Bis- (2,3-dioxypropylamine) 5- (M-methyloxy-acetylamino) -2,4,6-triiodoisophthalic acid or bis- (1,3 -dioxyisopropylamide) 5- (N-methyl-hS-hydroxypropionylamino) -2,4,6-triiodisophthalic acid 15-85 Rest Bis-oxyalkylamides 5- (N-alkyl-lb-hydroxyacyl) -2,4,6-triiodisophthalic acid general shape; w low viscosity and applied X-ray contrast media. Bis-oxyalkylamides of 5- (N-alkyl-ob-oxyaschamino) -2,4,6-triiodoisophthalic acid are obtained by reacting bis-dioxypropylamide 5-oi-oxyaccine-2, 4,6-triiodisophthalic acid of the general formula -CJO-CiH (OH) -R R., have the indicated value; A - lower acyloxy with the number of C atoms from 1 to 5 or a halogen atom;
    V CO - the reactive residue of an acid anhydride or anhydride halogen is reacted with di- or trioxyalkylamin-5.
    Bis-oxyalkylamide 5-o {, hydroxyacylamino-2, 4,6-triiodoisophthalic acid is reacted with an alkyl halide, alkyl sulfate or the corresponding sulfonic ester of sulfonic acid, for example, methane, benzene, or toluene sulfonic acid, in the presence of a base.
    Alkylating agents of formula 5 R; | - X are methyl bromide, methyl iodide, methyl chloride, dimethyl sulfate, methane-, benzene-, toluenesulfonic acid etheshbromide methyl ether, ethyl iodide, ethyl chloride, diethyl sulfate, 20 methane-methyl, benzene, ethyl acetate, ethyl chloride, ethyl sulfate, 20 methane-methyl, benzene, ethyl acetate, ethyl chloride, ethyl sulfate, 20 methane-methyl, benzene, ethyl acetate, ethyl chloride, ethyl sulfate, 20 methane methyl ether, benzene, ethyl tide, ethyl iodide, ethyl bromide; propyl iodide, propyl sulfate, propyl ether methane-, benzene-, toluenesulfonic acid, butyl bromide, butyl iodide, 25 dibutyl sulfate, butyl methanol benzene-, toluene sulfonic acid, amyl iodide, amyl bromide, methyl ether methane, cyclic benzene, methanol benzene, methylenediamine, propyl ether
    The strong acid released during the alkylation of ZO is strongly trapped by the base present. Strong alkalis, such as alkali metal alcoholates, alkali metal hydroxides (NaOH, KOH, LiOH), alkali metal carbonates (NajCOa KeCOi), quaternary ammonium hydroxides (tetramethylammonium hydroxide), are used as bases. The reaction is usually carried out in a polar solvent, such as water, lower alcohols (MeOH, ethylene glycol, propylene glycol, glycerin), lower glycol ethers (methoxyethanol, ethoxyethanol, butyloxyethanol, 45), ketones (acetone, methyl ethyl ketone, methyl isopropyl methyl ethyl ketone, methyl isopropyl methyl ethyl ketone, methyl isopropyl methyl ethyl ketone, methyl isopropyl methyl ethyl ketone (methyl acetone, methyl ethyl ketone (acetone, methyl ethyl ketone, methyl isopropyl ethoxyethanol, butylo 45 ethylene glycol)) tone) or exclusively in aprotic solvents such as geksametanol (MAT), 50 dimethyl formamide (DMF), dimethylacetamide (DMAC), dimethylsulfoxide (DMSO) or in mixtures of solvents. By heating the mixture, the reaction is accelerated.
    It is possible to prepare a reactive 55-derivative 5- (N-alkyl-in-oxyacylamino) -2,4,6-triyodisophthalic acid of general formula 1U, which
    then reacted with dioxypropylamine or its functional derivative and hydrolyzed.
    Suitable reactive acid derivatives for the said reaction are acid halides, in particular its acid chloride, i.e. 5- (K-alkyl-1-atsch1-oxyacyl) -2,4,6-triiodoisophthalic acid dichloride; or the corresponding anhydride with an organic or inorganic acid. Suitable organic acids are, for example, lower fatty acids, such as propionic, butyric, valeric, or carbonic half esters, such as monomethyl, monoethyl or monobenzyl carbonic ester. Suitable inorganic acids are hydrochloric acid, half esters of sulfuric acid, phosphoric and phosphorous acids, dialkyl esters of phosphorous acid, such as diethyl.
    The reaction of reacting with dioxypropylamine or its derivative is usually in an inert solvent, for example, such as DH, DMAC, at a temperature of from -10 to about 150 C.
    The following compounds are preferably used as oxyalkylamines or their derivatives: 1,3-dioxyisopropylamine (Serinol); 2,3-dioxypropylamine; tris - (- hydroxymethyl) -aminomethane 2-amino-2-hydroxymethyl-1,3-propanediol | as well as its kets or acetals, for example 5-amino-2,2-dimethyl-1, 3-dioxane, 4-aminomethyl-2,2-dimethyl-1, 3-dioxolane; 5-amino-2-methyl-1, 3-dioxane; 5-amino-2-phenyl-1,3-dioxane or 5-amino-1,3-dioxane.
    Example 1. Bis- (dioxyisopropylamide) b-5 (K-methyl-L-hydroxypropion-1-amino) -2,4,6-triiodoisophthalic acid.
    58.3 g of bis- (1,3-dioxyisopropylamide) b-5-y-hydroxypropionylamino-2,4,6-triiodoisophthalic acid is dissolved in 200 ml of water, and then a stoichiometric amount of 2N is added to the solution. caustic soda solution. The pH 11.9 solution is evaporated to dryness in vacuo. The residue consisting of the 5-N-sodium compound (sodium salt) of bis- (1,3-dioxyisoproxyamide) L-5-o-oxypropionylamino) -2,4,6-trdiodisophthalic acid is dried in vacuum at 100 C. J Equivalent weight for C, -j Hj calculated 799.27; found 799.08. The resulting sodium salt (60 g) is dissolved in 220 ml of dimethyl acetade (DMAC), and then 12.7 methyl iodide is added dropwise at 30 ° C. Thereafter, it was stirred for 1 hour at AO C, until the reaction was almost completed, which was monitored by chromatography. Then the solution is evaporated in vacuo. Syrup-like residue with stirring is introduced into 600 ml of acetone, and product (and sodium iodide) is precipitated. The resulting precipitate is filtered off, dissolved in 400 ml of water and finally completely desalted, passing the solution through a column loaded with cationite (for example, Amberlite IR 120) and then through a column loaded with anion exchanger (for example, Amber lite IR 45). Eluate enter dosu ha. The yield of the target product is 42.2 tons (71% of the theoretical). (after recrystallization from abs, ethanol) about 250 ° C (sintered at 190s). Thin layer chromatogram (TLC) on silica gel: solvent chloroform / methanol / ammonia (25%) 6: 3: 1. R / 0.29 and 0.33. Found,%: 47.99. Ci8 "24l3N Og Calculated,%: I, 48.12. Water solubility 100% (g / vol.) At. The same compound is obtained if the iodide methyl iodide described above is replaced with 11.4 g of dimethyl sulfate (0.09 mol) and proceeds further as described. Only methylation is limited to water-soluble bis- (1,3-dioxyisopropylamide) Bb-5 -oxypropionyl but-2,4,6-triiodoisophthalic acid to give bis- (1,3-dioxyisopropylamide) Bb-5- (H-methyl-oC- hydroxypropionyl amino) -2,4,6-triiodoisophthalic acid 298-EEP (with decomposition) R - 0.34 and 0.39 with CH2SED (MeOH) NHOH 6: 3: 1. This product can be very easily dissolved in water, but its solutions are supersaturated. Example 2. Bis- (1, E-dioxy-isopropyl-amide) b-5- (K-ethl-oxy52 propionylamino) -2,4,6-triiodisophthalic acid. 90 g of the 5 N-sodium compound of bis- (1,3-dioxyisopropylamide) L-5-a4-oxypropionylamino-2, 4,6-triiodoisophthalic acid in 240 ml of DMAC is reacted with 26.5 g of ethyl iodide and processed as in Example 1. 66 g of the title compound are obtained (73% of the theoretical). 295-297 ° C decomposition). TLC: R.f 0.27; Solvent СНСез (МеОН) НН4.0Н (25%) 6: 3: 1. Found,%: I 47,21. Calculated,%: I 47,29. tOjj 18.83 ° (with 10% in water). Example 3. Bis- (1,3-dioxy-isopropion I amide) L-5- (M-propyl-o4-oxypropionylamino) -2,4,6-triiodoisophthalic acid. 38 g of 5Y-sodium compound of bis- (1,3-dioxyisopropylamide) L-5- | 6-hydroxypropionylamino-2, 4,6-triiodoisophthalic acid in 120 ml of DMAC are reacted with 7.5 g of propyl bromide in a manner similar to Example 1 with the distribution between butanol and water desalted product. Yield: 18.43 g of the desired product, i.e. 50% theoretical. 149 ° C (sintered at 142s). TLC: Rf 0.35; 0.42 and 0.48. Solvent CH CP / CHCCj 10: 3. Found,%: I 46.25. C2o "gvCh08 Calculated,%: I 46,47. Water solubility 100% (g / vol.) At. Example 4. Bis- (1,3-dioxyisopropylamide) L-5- (L-butyl-og.-hydroxypropionylamino) -2,4,6-triiodoisophthalic acid. 80 g of sodium salt of bis- (1,3-dioxyl isopropylamide) L-5-1b-hydroxypropionylamino-2, 4,6-triiodoisophthalic acid in 240 ml DMAC is reacted with 17.8 g of butyl bromide at 40-80 ° C. Distribution between methyl ethylene and water (countercurrent extraction) desalted product. The output of 30 g of the target product. (after reshaping: awards from isopropanol / diisopropyl ether and re-reconstitution in water) UO-US C. those: R 0.36; 0.46 or 0.51. Solvent CH2Se2 / MeOH 10: 3. Found,%: I 45.88. Сг.Н оХ КЗОд Calculated,%: I 45,69. Water solubility 100% (g / vol.). Example 5. Bis- (1,3-dioxyisopropylamide) 5- (N-methyloxy-acetylamino) -2,4,6-triiodoisophthalic acid. 50 g of sodium salt of bis- (1,3-diocisisopropylamide) 5-H-hydroxyacetylamino-2, A, 6-triiodoisophthalic acid. in 250 ml of DMAC is reacted with 13.8 g of methyl iodide in the same way as Example 1. 37.9 g of bis- (1,3-dioxyis propshtamide) 5- (H-methyloxyacetylamino) -2,4,6-triiodoisophthalic acid are obtained, t . 77% of theoretical yield. 215-220 ° C. TLC: R 0.45. Solvent acetate / ice acetic acid / water 15: 3: 5. Found %: I 48.61. . Imprinted,%: I 48.99. Bis (1,3-dioxyisopropylamide) 5-hydroxy-acetylamino-2,4,6-triiodoisophthalic acid used as an intermediate product is prepared according to a known method. A) 59.6 g of 5-amino-2,4,6-triiodoisophthalic acid dichloride in a DMAC are reacted with 34 g of acetoacetamyl chloride to give 67.5 g of 5-acetoxyacetylamino-2, 4,6-triiodoisophthalic acid dichloride, with T " . 234-235 ° C. B) To 150 g of 5-acetoxy-acetylamino-2, 4,6-triiodoisophthalic acid dichloride in 810 ml of DMAC, add 80 g of tributylamine, and then 49.2 g of Serinol (1,3-dioxyisopropylamine) in 540 ml of DAC. 172 g of bis- (1,3-dioxyisopropylamide) 5-acetoacetate-acetylamino-2,4,6-triiodoisophthalic acid are obtained, which melts with decomposition at 190-192 s. This compound is weighed in water and carefully treated at 45 ° C with 1N. with a solution of caustic soda at pH 11 until complete hydrolysis of the acetoxy group. The resulting solution is desalted by percolation through a column with cation exchanger (Amberlite IR 12 and then through an anion exchanger column (Amberlite IR 45). The eluate is evaporated to dryness and then dissolved in 90% ethanol to give 73 g of the title intermediate in crystalline form. Trp 300 ° C (with decomposition). Example 6. Bis- (1, -3-dioxyisopropylamide) 5- (L-ethyl-hydroxyacetylamino) -2,4,6-triiodoisophthalic acid. The product is obtained by reacting 50 g of sodium salts of bis- (1,3-dioxyisopropylamide) 5-hydroxyacetylamino-2,4,6-triiodoisophthalic acid with ethyl iodide. Trd 210 ° C. Found,%: I 48.10. Calculated,%: 1 48.22. Example 7. Bis- (1,3-dioxyisopropyl amide) L-5- (L-metsh1-oh-oxypropionylamino) - 2,4,6-triiodoisophthalic acid (synthesis). To a solution of 14.5 g of L-5- (N-methyl-oC-acetotoxy-propio-amino) 2-dichloro-2,4,6-triyodisophthalic acid dichloride anhydrous acid in 35 ml with stirring at O 2 C is added dropwise 9.1 g of Serinol (1,3-dioxyisopropylamine) in 30 ml of DMF. Then it is stirred for another 3 hours at 20 ° C and the reaction mixture is finally evaporated until a syrup is formed. The residue crystallizes upon trituration with dichloromethane. The crude product is dissolved in 100 ml of water. Evacuation removed the solvent and at 40-50 C 2 n. With an aqueous solution of sodium hydroxide, the pH is adjusted to 11.6, and then hydrolysis is carried out. Continuously adding sodium hydroxide, maintain the pH at a constant level. A total of 29 ml of 2 N are consumed. caustic soda solution. The resulting alkaline solution is diluted with 200 ml of water and desalted by percolation, passing it through a column with cation exchanger (for example, Amberlite IR 120) and through a column with anion exchanger (for example, Amberlite IR 45). The eluate is evaporated to dryness. The output of 11.08 g of the target product, ie, 70% of theoretical yield. T (after re-recrystallization from b.e. anola) 280 ° C (baked at 210 ° C). those on silica gel: solvent ethyl acetate / ice on acetic acid / water 10: 5: 3. One spot at RJ 0.29. The L-5- (H-methyl-O6-acetoxypropionylamino) -2,4,6-triyodisophthalic acid dichloride used as the intermediate product was prepared as follows. A) 5-amino-2,4,6-triiodoisophthalic acid in sulfuric acid is treated with formaldehyde by a known method to obtain 5-methyl amino2, 4,6-triiodoisophthalic acid with mp 198-200 C. of those on silica gel with ethyl methyl ketone / ethanol solvent / water / ice on acetic acid 20: 8: 5: 1,5. R. 0.55 B) 23 g of 5-methylamino-2,4,6-triiodoisophthalic acid are boiled at reflux at 120 ml of thionyl chloride in the presence of 0.1 ml of quinoline for 7 hours. After complete removal of the thionyl chloride, the residue is added with stirring to 120 g of ice-cold water containing 125 g of common salt and 12 g of sodium bicarbonate. The resulting product is extracted with 200 ml of ethyl acetate. From the extract by concentration, 5-methylamino-2,4,6-triiodoisophthalic acid dichloride is obtained. 167 C, those on silica gel with benzene / hexane solvent 1: 1; Rf 0.50. Found,%: Cg 11.74; ; j .62,74. i3NOo B15 number D: SS 11.62; J 62.44. B) To 12 g of 5-methyl-amino-2,4,6-triiodoisophthalic acid dichloride in 30 ml of DMAC, L-otr-acetoxypropionic acid chloride is added dropwise. Then stir another 1-2 hours at 20 ° C. The reaction solution was added while stirring to ice water. The precipitated product is filtered off, dried and recrystallized from a small amount of benzene. Thus, 14gdichlr a nhydride b-5- (N-methyl-1-acetoxypropionylamino) -2,4,6-triiodoisophthalic acid with T d187-190 C. is obtained on silica gel with hexane / chloroform / ethyl acetate 3: 1: one; 2 spots at 1C 0.22 and 0.5. Found,%: eb 9.80; I 52.46. Calculated,%: EB 9.76; I 52.59. Example 8. Bis- (2,3-dioxypropylamide) L-5- (N-methyl) i-oxypropionyl) -2,4,6-triiodisophthalic acid. 14.4 g of L-5- (Nmethyl-about-acetoxypropionylamino) -2,4,6-triiodoisophthalic acid dichlorohydride in 30 ml of DMF dissolved 9.4 g of 2,3-dioxypropylamine (1-amino-2,3 - propane diol). 50 ml of DMF are added to the solution, after which it is subjected to the treatment described in Example 7. 10.8 g of the expected product are obtained, i.e. 68% of theoretical yield. TSP (after recrystallization from ethanol) (baked at). those on silica gel: solvent ethyl acetate / ice on acetic acid / water 10: 5: 3. One spot at R 0.45. Found,%: 1, 47; HgO 2.8. Calculated,%: I 47,05; H 0 0 2.23. Example 9. Vis- (2,3-dioxypropylamide) 5- (M-methyloxyacetomylamino) -2,4,6-triiodoisophthalic acid. To the 5-X-sodium compound of bis- (2, E-dioxypropylamide) 5-hydroxyacetylamino-2, 4,6-triiodoisophthalic acid (49 g) in 250 ml of DMAC, prepared analogously to example 1, is added dropwise at 25 e 13.5 g of methyl iodide, and then the mixture is stirred for a few more hours. The reaction mixture is evaporated in vacuo. 300 ml of methylene chloride is added to the residue, as a result of which the formed product is precipitated in a mixture with sodium iodide, the crude product is dissolved in water and desalted using an ion exchanger. 36 g of bis- (2,3-dioxyproshamid) 5- (M-methyloxy-acetylamino) -2,4,6-triiodoisophtapic acid are obtained, i.e. 75% of theoretical. T {.d 190 191 e (amorphous product). those on silica gel: solvent 2-butanone / ice on acetic acid / water 15: 3: 5. Spot at the value of {0.48 and 0.40. Solubility: the product is very easily dissolved in water and methanol, but only limited in ethanol (20 parts by volume at boiling point and 35 parts by parts at). Used as an intermediate, bis- (2,3-dioxypropylmide) 5-hydroxy-acetylamino-2,4,6-triiodoisophthalic acid is prepared according to a known method.
    2A, 4 g of 5-acetoxy-acetylamino-2, 4,6-triiodoisophthalic acid dichloride in 60 ml of DMAC with stirring, NII dropwise added to a solution of g of 2,3-dioxypropylamine (1-amino-2, 3-dioxypropane) in .100 ml DMAc.
    An oily bis- (2,3-dioxypropylamide) 5-acetoxyacetyamine-2, 4,6-triiodoisophthalic acid is obtained. This compound is dissolved in 250 ml of water and carefully treated with 40 ml of 1 and. solution of caustic natrdo complete hydrolysis of the acetoxy group.
    The resulting solution is desalted by percolation, passing it first through a column with cation exchanger (Amberlite IR120), and then through a column with anion exchanger (Amberlite IR 45). The eluate is evaporated. After some time, crystallization is carried out. Recrystallization from a small amount of water gives the desired intermediate product, bis- (2,3-dioxypropylamide) 5-hydroxyacetate-2,4,6-tri-iodo-isophthalic acid (19.4 g) in pure form. T (c 290 ° C.
    TLC: R 0.24; solvent is ethyl acetate / ethanol / ammonia (25%) 15: 7: 6.
    Found,%: C 25.01; I 49.75.
    C 6 "2obN 08
    Calculated,%: C 25.18; I 49.89.
    Example 10. Bis- (2,3-dioxypropnlamide) 5- (M-methyloxyacetylamino) -2,4,6-triiodoisophthalic acid.
    A) 90 g of bis- (2,3-dioxypropylamide) 5-hydroxy-acetylamino-2,4,6-triiodoisophthalic acid are suspended in 700 ml of DMAC. At 4 CgS, 95 g of sodium hydroxide solution in methanol are added to the suspension. Forms a 5-M-sodium compound. The methanol, the reaction water and part of the DMAC are distilled off in vacuo. 496 g of a solution containing 0.234 mol of the 5-N-sodium compound of the bis- (2,3-dioxypropylamide) 5-hydroxy-acetylamino-2,4,6-triiodoisophtapic acid are obtained.
    B) To a solution of 13 g of methyl bromide in 160 g of DMAC with stirring while dropping for 45 minutes 390 g (0.091 mol) of the solution described above, and then stirred for several hours at 0-5 ° C. The treatment is carried out according to Example 9.
    60.1 g of bis- (2,3-dioxypropylamide) 5- (N-methyloxy-acetylamino) -2,4,6-triiodoisophthalic acid are obtained, i.e. 85% of theoretical.
    TLC on silica gel, solvent ethyl acetate / ice on acetic acid / water 10: 5: 3. Spot at a value of R.J 0.3 and 0.45. The product can be recrystallized from 95% ethanol. Tf, 305-310 C (with decomposition).
    C) To a solution of 13.8 g (0.109 mol) of dimethyl sulfate in 150 ml of DMAC with stirring for 50 minutes, 390 g of the solution of the sodium compound of bis- (2,3-dioxypropylamide) 5-hydroxy-acetylamino-2 described above is added dropwise , 4,6-triiodoisophthalic acid. The reaction mixture is stirred for several hours, and then it is processed in example 1.
    62.4 g of bis- (2,3-dioxypropylamide) 5 - (} {- methyloxy-acetyl instant) -2,4,6-triiodoisophthalic acid are obtained, i.e. 88% of theoretical. TSN (after recrystallization from 95% ethanol) 305-310 C (with decomposition).
    Example 11. Bis- (2,3-dioxypropylamide) 5- (M-methyloxyacetylamino) -2,4; 6-triiodoisophthalic acid.
    To a solution of 18.2 g of 1-amino-2,3, propanediol in 70 ml of DMAC with stirring at 5 ° C for 45 minutes, 28.4 g of 5- (M-methylacetoxy acetylamino) -2, 4, dropwise are added dropwise. 6-triiodisophthalic acid in 90 ml DMAC. The reaction mixture is stirred for a few more hours and then evaporated in vacuo to form a syrup. The residue is triturated with methylene chloride and acetone, then decanted with a solvent. By vacuum treatment, the residue is freed from the solvent, and then it is dissolved in 200 ml of water and maintained at a pH of 11-11.5, carefully adding only 50 ml of 2 N at 45 ° C. caustic soda solution, as a result of which the acetoxy group is hydrolyzed.
    The resulting solution is desalted by percolation, passing it through a column with cation exchanger (for example, 200 ml Amberlite IR 120), and then through another column with anion exchanger (for example, 250 ml Amberlite IR 45). The eluate is evaporated, the residue is dissolved in methanol: Methylene chloride is then added to the solution, with the result that the desired product precipitates. Yield 22 g of the title compound, i.e. 190 C from the theoretical. Tshch about (sintering occurs at 165C). those on silica gel: solvent 2-butanone / ice on acetic acid / water 15: 3: 5, Ptn at R 0.48 and 0.40. Found,%: I 48.69. St “2i4Va Calculated,%: 148.99. The compound is very easily dissolved in water and methanol (100% g / vol). The 5- (-methylacetoxy-acetylamino) -2,4,6-triyodisophthalic acid dichloride used as an intermediate was prepared as follows. To 32 g of 5-methylammono-2,4,6-triiodoisophthalic acid dichloride in 80 ml of DMAC, while moving at 0–5 ° C, 10.7 g of acetoxyacetyl chloride are added dropwise. The mixture is then stirred at room temperature overnight. While stirring, the reaction solution is added to ice water and 36.7 g of 5- (N-methylacetoxy-acetylamino) -2,4,6-triiodoisophthalic acid dichloride are obtained with Tc 198-200 ° C. Output 98.8% of theoretical. those on silica gel with benzene-methanol solvent 10: 3; R 0.64. Found,%: CC 10.05; I 53.41. C, HgCe2l, NO Calculated,%: C 9.9; I 53.3. o Example 12. Bis- (2,3-dioxypropylamide) 5- (1-methyloxyacetate but) -2, A, 6-triiodisophthalic acid A) Bis-2,3-isopropylidenedioxypropylamide) 5- (M-methyloxyacetylamine) - 2,4,6-triiodoisophthalic acid or bis-2,4-dimethyl-1,3, -dioxolane - (4) -shetylamide 5- (M-methyloxy-acetylamino) -2,4,6-triiodoisophthalic acid. To 17.8 g of 5- (N-.-Methyl-acetoxy-acetylamino) -2,4,6 -triiodisophthalic acid dichloride in 50 ml DMAC at 5-8 ° C with a stirring and add dropwise a solution of 16 g of 4-aminomethyl-2 , 2-dimethyl-1,3-dioxolane. The mixture is stirred for 18 hours at room temperature, then the hydrochloride precipitated in the precipitate is removed and the filtrate is evaporated completely under vacuum. The residue was suspended in water, filtered, dissolved in an aqueous solution of methanol and treated with 2N. with a solution of caustic soda at 50-55 s and a pH value of 10.5-11.0, and the acetoxy group is fully hydrolyzed. The hydrochloric acid was carefully added, the resulting solution was brought to neutrality in water, and the bis (2,3-isopropylidenedioxypropylamide) 5- (N-methylox1 acetylamino) -2,4,6-triyodisophthalic acid crystallized out. Yield 15.2 g, i.e. 71% of theoretical. (after recrystallization from dilute methanol) 180-181 C. TLC: R 0.295, solvent chloroform / hexane / methanol 3: 3: 1. Found,%: I 44.08. S "obN3 ° s Calculated,% g I 44.41. This compound is very easily dissolved in methanol, ethanol and chloroform, but poorly soluble in water. B) Bis- (2,3-dioxypropylamide) 5- (M-methyloxyacetylamino) -2,4,6-triiodoisophthalic acid. 15 g of bis- (2,3-isopropylidenedioxypropylamide) 5- (W-methyloxy-acetylamino) -2,4,6-triiodoisophthalic acid is dissolved in a solution of 185 ml of 0, 1N, aqueous hydrochloric acid and 185 ml of methanol and with stirring incubated for 5 h at 50s. Percolation of the reaction solution is freed from hydrochloric acid, passed through a column with 75 ml of weakly basic ion exchanger, for example, Amberlite 45, and evaporated to dryness. 12.2 g of bis- (2,3-dioxypropane amide) 5- (M-methyloxy-acetylamino) -2,4,6-triiodoisophthalic acid are obtained, i.e. 90% of theoretical C 190 (amorphous product). cheskogo. from 95% recrystallization ethanol 300 С (with decomposition). Among the compounds described in the examples, preference is given in the application of bis- (oxyalkyl almonds) 5- (N-methyl-c-oxyacylamino) -2,4,6-triiodoisophthalic acid of formula (111), since they are better than the higher N-alkyl derivatives dissolve in water and more readily available. Among the compounds of the formula (111), the hydroxyacetyl derivatives are usually preferred by the hydroxypropionyl derivatives, since they are prepared in a simpler way, they have the required high water solubility. Among oxyalkylamides, 2,3-dioxypropylamides are preferred due to their simplicity. A typical representative of this group is bis- (2,3-dioxypropylamide) 5- (11-methyloxyacetylamino) -2,4,6-triiodisophthalic acid (compound A), compared to other with compounds, it is characterized by very high water solubility, low viscosity of its aqueous solutions, and high stability. in tab. Figures 1 and 2 show the properties of the compound and two other known non-ionic X-ray agents, namely B) bis- (1,3, -dioxyisopropylamide li, -5-o1-oxypropionylamino-2, A, 6-triiodisophthalic acid and B) 3- acetyl amino-4-methyl acetylamino-2,4,6-triyodbenzoylglucosamine. Table 1 From table. 1 that compound A obtained according to the invention has a higher solubility in water and a significantly lower viscosity than the known compounds B and B. Consequently, solutions of compound A can be used in higher concentrations, and their injection injection is due to the low viscosity does not create difficulties. From tab. 2 that the osmotic pressure of the compound A obtained according to the invention is lower osmotic pressure of the known compound. Consequently, the body load when giving compound A is lower than when giving compound B. Bis (oxyalkylamides) 5- (M-alkyl-oC-hydroxyacylamino) -2,4,6-triiodoisophthalic acid of general formula (11) are used mainly in the form of their aqueous solutions. Depending on the type of prescription, 15-85% solutions (g / vol, i.e. 100 g of a contrast agent per 100 ml of solution) with an iodine content of OT-vSO4 / 420 mg / ml are used. Preference is given to concentrated solutions. The type of input depends on the body that should be visible. For vasography, solutions are injected or poured into the appropriate blood vessels. For urography, solutions are injected or infused intravenously. To enhance contrasts in computer tomography, the solutions, depending on the contrast (organ or tissue) to be strengthened, are either administered intravenously into the circulation or selectively injected into the bloodstream of a separate organ or into the body cavity. For myelography and radiculography, the solutions are instilled after lumbar or suboccipital puncture. In ventriculography, punctures are right.
    Dosage: myelography "v5 - 15 ml; radiculography (vS - 5 ml; ventriculography / V1 - 2 ml.
    The preparation of solutions of remittance contrast agents is simple, since it eliminates the need for the manufacture of brines.
    Pure amides of 2,4,6-triiodioephthalic acid, obtained according to the described examples, are dissolved, for example, under sterile conditions in the required quantity twice
    Ingredients and properties
    distilled water, filtered, poured into bottles for serum or ampoules and then sterilized. The proposed triiodisophthalic acid amides do not decompose when sterilized at high temperature.
    Example 13. The composition of the injection solutions containing bis- (2,3-dioxypropylamide) 5- (y-methyloxyacetylamino) -2,4,6-triiodoisophthalic acid (compound A) is presented in table 3.
    .Table 3
    Solutions (20 ml each) containing iodine, mg / ml
    Compound A, g
    Dinatrieva - calcium salt of ethylenediaminetetraacetic acid hexahydrate, mg
    Tromethamine Tris- (hydroxymethyl; -ami
    200
    300
    420
    12.25
    17,15
    11.0
    7,8
    权利要求:
    Claims (1)
    [1]
    X-ray contrast agent containing a contrast agent and water, characterized in that, in order to increase water solubility and lower viscosity, it contains bis- (2,3-dioxipropylamide) 5- (I-methyloxyacetylamino) -2,4, 6-triiodisophthalic acid or bis- (1,3-dioxiisopropylamide) 5- (N-methyl-sb-hydroxypropionylamino) -2,4,6-triiodisophthalic acid in the following ratio of ingredients, wt.%:
    Bis- (2,3-dioxipropylamide) 5- (N-methoxyacetylamino) -2,4,6-triiodisophthalic acid or bis- (1,3-dioxyisopropylamide) 5- (I-methyl-os-hydroxypropionylamino) -2,4 6-triiodisophthalic acid 15-85
    Water rest in
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1087052A3|1984-04-15|X-ray contrast device
    US4352788A|1982-10-05|Derivatives of 2,4,6-triiodo-isophthalic acid, processes for their synthesis and X-ray contrasting materials containing these
    JP4615866B2|2011-01-19|Crystal form of N- | -D-phenylalanine
    ES2618677T3|2017-06-21|Substituted beta-phenyl-alpha-hydroxy-propionic acid, synthesis method and its use
    US4426371A|1984-01-17|Novel N-hydroxyalkylated dicarboxylic acid bis|, as X-ray contrast media
    CA1079723A|1980-06-17|Polygalactosido-sucrose poly | sulfate salts
    US4017608A|1977-04-12|Therapeutic composition and method of therapeutically treating warm blooded animals therewith
    US4454123A|1984-06-12|O-xylopyranoside series compounds and methods of use
    RU2046798C1|1995-10-27|Derivatives of glutathione-s-lower saturated acid and a method of their synthesis
    US3268582A|1966-08-23|Phenylalkyl-carboxylic acid amides
    US4083996A|1978-04-11|Novel hydroxamic acid derivatives and medicaments for treatment of urolithiasis and pyelonephrosis comprising such derivatives
    HU229161B1|2013-09-30|Lipophilic diesters of chelating agents
    KR970011452B1|1997-07-11|Substituted dicarboxylic acids-bis|, and x-ray contrast agents containing them
    US4157396A|1979-06-05|Hydroxamic acid derivatives and medicaments for treatment of urolithiasis and pyelonephrosis comprising such derivatives
    CA1117867A|1982-02-09|Pharmaceutical compositions containingtetrahydrotriazine diones
    AU2008278337B2|2011-09-29|Novel sulfonated sugar compound and use thereof as medicine
    CH644613A5|1984-08-15|MONO | | - | phosphonate, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN.
    US4424348A|1984-01-03|Methods of manufacture of nitrile-containing glucuronic acid conjugates
    Scattergood et al.1940|Glycofuranosides and Thioglycofuranosides. VII. Crystalline Alkyl Furanosides and Dimethylacetal of d-Mannose
    US4275192A|1981-06-23|Bis|dihydrazone derivatives and pharmacologically acceptable salts thereof
    DE3919259A1|1990-12-20|CRYSTALLINE CEPHEM ACID ADDITION SALTS AND METHOD FOR THE PRODUCTION THEREOF
    SU805949A3|1981-02-15|Method of preparing 4-aminooleandomycin derivatives or their salts
    RU2108336C1|1998-04-10|Phospholipid derivatives, method of their synthesis, pharmaceutical composition and a method of its preparing
    JP3176720B2|2001-06-18|Method for producing and purifying drug having anti-neoplastic activity, octadecyl- [2- | -ethyl] -phosphate, and method for preparing drug
    CS195746B2|1980-02-29|Process for preparing crystalline methanolate of natrium salt of cephamandole
    同族专利:
    公开号 | 公开日
    IT1207226B|1989-05-17|
    ES8106136A1|1981-08-01|
    EP0023992B1|1982-06-23|
    SU1116975A3|1984-09-30|
    NO149171C|1984-02-29|
    AU537446B2|1984-06-21|
    FI802374A|1981-02-10|
    PL126667B1|1983-08-31|
    PT71683B|1981-06-11|
    EP0023992A1|1981-02-18|
    PL226144A1|1981-10-16|
    CA1123009A|1982-05-04|
    IE801683L|1981-02-09|
    JPS5629554A|1981-03-24|
    IE50148B1|1986-02-19|
    NO802374L|1981-03-26|
    PT71683A|1980-09-01|
    DK157190B|1989-11-20|
    AR223890A1|1981-09-30|
    DK157190C|1990-04-23|
    DK343880A|1981-02-10|
    DE3060592D1|1982-08-12|
    YU42977B|1989-02-28|
    US4348377A|1982-09-07|
    FI73200C|1987-09-10|
    YU201280A|1983-02-28|
    AT1234T|1982-07-15|
    JPS5935913B2|1984-08-31|
    AU6103880A|1981-02-12|
    FI73200B|1987-05-29|
    NO149171B|1983-11-21|
    ES494077A0|1981-08-01|
    IT7925027D0|1979-08-09|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    SE344166B|1966-12-13|1972-04-04|Pharmacia Ab|
    SE315975B|1967-12-28|1969-10-13|Pharmacia Ab|
    US3886859A|1974-04-26|1975-06-03|Gen Electric|Compactor brake|
    CH608189A5|1974-12-13|1978-12-29|Savac Ag|
    FI760068A|1975-02-03|1976-08-04|Schering Ag|
    GB1548594A|1976-06-11|1979-07-18|Nyegaard & Co As|Triiodoisophthalic acid amides|
    DE2628517C2|1976-06-23|1985-02-21|Schering AG, 1000 Berlin und 4709 Bergkamen|Dicarboxylic acid bis compounds, process for their preparation and X-ray contrast media|
    CH626873A5|1977-03-28|1981-12-15|Bracco Ind Chimica Spa|US4396598A|1982-01-11|1983-08-02|Mallinckrodt, Inc.|Triiodoisophthalamide X-ray contrast agent|
    US5204086A|1982-10-01|1993-04-20|Nycomed Imaging As|X-ray contrast agent|
    LU88639I2|1982-11-08|1996-02-01|Nycomed Imaging S A|Contrast agents for x-rays|
    US5191119A|1983-10-20|1993-03-02|Cook Imaging Corp.|Process for producing non-ionic radiographic contrast media utilizing N-allylation|
    JPH0662472B2|1984-01-31|1994-08-17|三井東圧化学株式会社|Polyoxyalkylene compound and method for producing the same|
    AU618535B2|1987-05-22|1992-01-02|Bracco International B.V.|Preparation of 5-acylamino-2,4,6-triiodo-or tribromo-benzoic acid derivatives|
    DE3731542A1|1987-09-17|1989-03-30|Schering Ag|NEW DICARBONIC ACID-BIS , METHOD FOR THE PRODUCTION THEREOF AND THESE CONTAINING X-RAY AGENTS|
    DE3739098A1|1987-11-16|1989-05-24|Schering Ag|NEW SUBSTITUTED DICARBONIC ACID-BIS , METHOD FOR THE PRODUCTION THEREOF AND THEIR CONTAINING X-RAY CONTRASTING AGENTS|
    JPH02126118U|1989-03-28|1990-10-17|
    JPH036623U|1989-06-05|1991-01-23|
    US5232685A|1989-11-03|1993-08-03|Schering Aktiengesellschaft|Nonionic x-ray contrast medium with high iodine content|
    FR2673180B1|1991-02-25|1994-03-04|Guerbet Sa|NOVEL POLY-IODIC NON-IONIC COMPOUNDS, PREPARATION METHOD, CONTRAST PRODUCT CONTAINING THE SAME.|
    IT1252180B|1991-12-10|1995-06-05|Bracco Ind Chimica Spa|5,5 '-BISACETYLIMINE) -BIS , THEIR METHOD OF PREPARATION AND ROENTGENOGRAPHIC CONTRAST MEANS THAT CONTAIN THEM|
    IT1274027B|1994-03-03|1997-07-14|Zambon Spa|PROCESS FOR THE PREPARATION AND PURIFICATION OF IODURATED CONTRAST MEANS|
    GB9419203D0|1994-09-23|1994-11-09|Nycomed Innovation Ab|Contrast media|
    US6310243B1|1994-09-23|2001-10-30|Nycomed Imaging As|Iodinated x-ray contrast media|
    AU702895B2|1995-05-23|1999-03-11|Bracco Imaging S.P.A.|Process for the preparation of a dicarboxylic acid dichloride|
    US5575905A|1995-05-24|1996-11-19|Nycomed Imaging As|Iodination process|
    GB9618056D0|1996-08-29|1996-10-09|Nycomed Imaging As|Process|
    US5847212A|1997-04-21|1998-12-08|Abbott Laboratories|Process for the preparation of iohexol|
    US20040170561A1|1998-09-08|2004-09-02|Jesse Salb|Functional radiographic imaging methods and agents|
    US20010038682A1|1998-09-08|2001-11-08|Jesse Salb|Radiographic assessment of tissue response to compounds|
    US6226352B1|1998-09-08|2001-05-01|Veritas Pharmaceuticals, Inc.|System and method for radiographic imaging of tissue|
    US6751290B2|1998-09-08|2004-06-15|Veritas Pharmaceuticals, Inc.|Radiographic assessment of tissue after exposure to a compound|
    US6723746B2|1998-09-08|2004-04-20|Veritas Pharmaceuticals, Inc.|Functional radiographic imaging methods and agents|
    SE520688C2|2000-04-11|2003-08-12|Bone Support Ab|An injectable bone mineral replacement material|
    SE517168C2|2000-07-17|2002-04-23|Bone Support Ab|A composition for an injectable bone mineral replacement material|
    IT1319671B1|2000-12-01|2003-10-23|Bracco Spa|PROCESS FOR THE PREPARATION OF-N, N'-BISETIL) -5 -AMINO)|
    SE522098C2|2001-12-20|2004-01-13|Bone Support Ab|Artificial bone mineral substitute material useful as an X-ray contrast medium comprises ceramic and water soluble non-ionic X-ray contrast agent|
    ES2289172T3|2001-12-20|2008-02-01|Bone Support Ab|A NEW BONE MINERAL SUBSTITUTE.|
    SE0300620D0|2003-03-05|2003-03-05|Bone Support Ab|A new bone substitute composition|
    SE0302983D0|2003-11-11|2003-11-11|Bone Support Ab|Apparatus for providing spongy bone with bone replacement and / or bone strengthening material and associated method|
    SE527528C2|2004-06-22|2006-04-04|Bone Support Ab|Apparatus for the preparation of curable pulp and use of the apparatus|
    US7955234B1|2007-02-28|2011-06-07|Pursley Michael G|Exercise device and method|
    CN103951585A|2007-07-12|2014-07-30|通用电气医疗集团股份有限公司|Contrast agents|
    JP2011500532A|2007-10-12|2011-01-06|ジーイー・ヘルスケア・アクスイェ・セルスカプ|Contrast agent|
    JP2011500530A|2007-10-12|2011-01-06|ジーイー・ヘルスケア・アクスイェ・セルスカプ|Contrast agent|
    US20100209356A1|2007-10-12|2010-08-19|Duncan George Wynn|Contrast agents|
    EP2200656B1|2007-10-12|2012-12-05|GE Healthcare AS|Contrast agents|
    US9180137B2|2010-02-09|2015-11-10|Bone Support Ab|Preparation of bone cement compositions|
    WO2012136813A2|2011-04-07|2012-10-11|Universitetet I Oslo|Agents for medical radar diagnosis|
    CN102887833B|2011-07-21|2014-10-22|浙江司太立制药股份有限公司|Iodine-containing dimer contrast medium|
    US10294107B2|2013-02-20|2019-05-21|Bone Support Ab|Setting of hardenable bone substitute|
    EP3220887A1|2014-11-21|2017-09-27|Technical University of Denmark|Gel formulations for local drug release|
    US10610366B2|2015-01-29|2020-04-07|Theracell, Inc.|Demineralized bone fiber composition for use in minimally invasive surgery|
    AU2017266410A1|2016-05-20|2018-11-22|Nanovi Radiotherapy Aps|Palpable marker composition|
    US10639157B2|2017-03-14|2020-05-05|Theracell, Inc.|Demineralized bone fiber composition for use in minimally invasive surgery|
    WO2020249801A1|2019-06-12|2020-12-17|Technical University Of Denmark|Dissacharide formulations for controlled drug release|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    IT7925027A|IT1207226B|1979-08-09|1979-08-09|2,4,6-TRIIODE-ISOPHTHALIC ACID DERIVATIVES, METHOD FOR THEIR PREPARATION AND CONTRAST MEANS THAT CONTAIN THEM.|LV920082A| LV5116A3|1979-08-09|1992-07-28|X-ray contrast device|
    [返回顶部]